留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

基于机器学习的高血压风险识别模型构建、验证及可解释性研究

李文俊,  方浪,  姬燕梅,  杨美蓉,  蒙妮,  刘心怡,  金醒昉

李文俊, 方浪, 姬燕梅, 杨美蓉, 蒙妮, 刘心怡, 金醒昉. 基于机器学习的高血压风险识别模型构建、验证及可解释性研究[J]. 昆明医科大学学报.
引用本文: 李文俊, 方浪, 姬燕梅, 杨美蓉, 蒙妮, 刘心怡, 金醒昉. 基于机器学习的高血压风险识别模型构建、验证及可解释性研究[J]. 昆明医科大学学报.
Wenjun LI, Lang FANG, Yanmei JI, Meirong YANG, Ni MENG, Xinyi LIU, Xingfang JIN. Construction,Validation,and Explainability Study of A Hypertension Risk Identification Model Based on Machine Learning[J]. Journal of Kunming Medical University.
Citation: Wenjun LI, Lang FANG, Yanmei JI, Meirong YANG, Ni MENG, Xinyi LIU, Xingfang JIN. Construction,Validation,and Explainability Study of A Hypertension Risk Identification Model Based on Machine Learning[J]. Journal of Kunming Medical University.

基于机器学习的高血压风险识别模型构建、验证及可解释性研究

基金项目: 国家自然科学基金(81460209);云南省科技厅-昆明医科大学应用基础研究联合专项基金(202401AY070001-320);云南省科技厅中央引导地方科技发展资金(202307AB110005);昆明市卫生科技人才培养项目医学科技学科后备人才(2023-SW(后备)-10)
详细信息
    作者简介:

    李文俊(1992~),女,云南昆明人,医学博士,主治医师,主要从事心血管病研究工作

    通讯作者:

    金醒昉,E-mail:jinxf177@126.com

  • 中图分类号: R544.1

Construction,Validation,and Explainability Study of A Hypertension Risk Identification Model Based on Machine Learning

  • 摘要:   目的  基于机器学习(machine learning,ML)构建高血压风险识别模型并进行开发、验证,以识别高血压风险人群,探究最优模型在临床应用中的潜力。  方法  于2019年9月至2023年12月在云南地区进行慢性病横断面调查,选取云南省多民族聚居区35~75岁常住居民为调查对象,采用分层整群抽样方法进行抽样。该调查包括1435名参与者,数据预处理后共包含848名研究对象,调查期间收集了有关社会人口统计学、吸烟和饮酒史、慢性疾病和药物使用的数据。数据集按8:2随机划分为训练集和测试集,开发了逻辑回归(logistic regression ,LR)、决策树(decision tree ,DT)、随机森林(random forest ,RF)、极端梯度提升(eXtreme gradient boosting,XGBoost)、分类提升(categorical boosting,Cat Boost)和多层感知器(multilayer perceptron,MLP)等六种ML模型。通过网格搜索和五折交叉验证优化超参数,模型性能通过准确率、敏感度、特异度、F1值、受试者工作特征曲线下面积(area under curve,AUC及95%CI)、决策曲线分析(decision curve analysis,DCA)和校准曲线进行综合评估。对最优模型采用沙普利加性解释(SHapley additive explanations,SHAP)进行可解释性分析,并进行了小样本初步探索性泛化验证。  结果  共纳入848名患者,模型纳入社会人口学、体格检查及血液生化指标等特征,在测试集上RF模型表现最佳,其准确率为0.926,特异度为0.943,F1-Score为0.923,AUC值为0.972(95%CI:0.950~0.993,$ P<0.05 $)。DCA分析显示RF模型在广泛的阈值范围内具有最高临床获益,SHAP分析揭示了年龄、体重、血脂、血糖、尿酸等是识别高血压的关键特征($ P<0.05 $)。在20例探索性泛化验证数据中,RF模型达到了100%的识别准确率。多变量Logistic回归分析证实,药物使用史(OR=16.837,95%CI:11.344~24.990)、收缩压(OR=1.032,95%CI:1.019~1.044)和尿酸(OR = 1.005,95%CI:1.003~1.008)是高血压的独立危险因素($ P<0.05 $)。  结论  基于随机森林算法构建的机器学习模型在内部测试中表现出良好的判别效能,可为临床高血压的辅助筛查与多维特征量化提供参考,但其临床泛化效能仍需大样本前瞻性队列进一步确证。
  • 图  1  各模型混淆矩阵比较

    A: LR;B: RF;C: DT;D: CatBoost;E: XGBoost;F: MLP。

    Figure  1.  Comparison of confusion matrices for each model

    图  2  六种机器学习模型ROC曲线

    Figure  2.  ROC curves of six machine learning models

    图  3  六种机器学习模型的临床决策曲线(DCA)和校准曲线比较

    A:决策曲线分析;B:校准曲线。

    Figure  3.  Comparison of Decision Curve Analysis (DCA) and calibration curves of six machine learning models

    图  4  RF模型SHAP可解释性分析

    A: 特征分布摘要散点图;B: 全局特征重要性条形图。

    Figure  4.  SHAP interpretability analysis of the RF model

    图  5  RF模型SHAP分析力图(选取高血压患者样本)

    Figure  5.  SHAP force plot of the RF model (sample from a hypertensive patients)

    表  1  健康组与高血压组人口统计学和临床特征比较[($ \bar x \pm s $)/n(%)]

    Table  1.   Comparison of demographic and clinical characteristics between the healthy group and the hypertension group [($ \bar x \pm s $)/n(%)]

    变量总数(n=848)健康组(n=510)高血压组(n=338)t/χ2P
    女性532(62.7)342(67.1)190(56.2)10.2280.001*
    彝族585(69.0)344(67.5)241(71.3)4.4310.219
    服药史405(47.8)115(22.5)290(85.8)325.943<0.001*
    饮酒史174(20.5)106(20.1)68(20.1)0.0550.814
    吸烟史167(19.7)100(19.6)67(19.8)0.0060.939
    饮茶史290(34.2)167(32.7)123(36.4)1.2000.273
    糖尿病史235(27.7)139(27.3)96(28.4)0.1340.715
    年龄(岁)59.10 ± 10.6757.28 ± 10.8661.86 ± 9.76−6.260<0.001*
    体重(kg)58.68 ± 11.0156.88 ± 10.6861.39 ± 10.96−5.969<0.001*
    身高(cm)155.67 ± 8.65155.44 ± 8.84156.01 ± 8.36−0.9290.353
    BMI24.26 ± 5.7023.66 ± 6.5825.18 ± 3.87−3.835<0.001*
    收缩压(mmHg)130.11 ± 30.13120.87 ± 12.11144.06 ± 41.65−11.847<0.001*
    舒张压(mmHg)80.09 ± 17.6875.48 ± 8.5287.04 ± 24.40−9.831<0.001*
    白细胞计数(109/L)6.57 ± 1.916.40 ± 1.876.82 ± 1.95−3.1430.002*
    总胆固醇(mmol/L)5.44 ± 1.135.35 ± 1.085.57 ± 1.20−2.7680.006*
    低密度脂蛋白(mmol/L)3.21 ± 0.873.16 ± 0.853.30 ± 0.91−2.3210.021*
    甘油三酯(mmol/L)1.95 ± 2.141.80 ± 2.062.18 ± 2.25−2.5600.011*
    高密度脂蛋白(mmol/L)1.50 ± 0.421.53 ± 0.421.45 ± 0.412.7780.006*
    红细胞计数(×1012/L)4.88 ± 0.494.84 ± 0.504.95 ± 0.48−3.1680.002*
    红细胞压积(%)46.19 ± 4.7345.65 ± 4.8947.02 ± 4.36−4.171<0.001*
    肌酐(μmol/L)72.77 ± 32.7269.35 ± 13.6977.93 ± 48.60−3.766<0.001*
    淋巴细胞计数(×109/L)25.23 ± 14.9325.06 ± 14.8825.50 ± 15.04−0.4190.675
    尿素(mmol/L)5.41 ± 1.675.29 ± 1.495.58 ± 1.90−2.5020.013*
    尿酸(μmol/L)318.09 ± 89.31300.85 ± 77.36344.10 ± 99.40−7.104<0.001*
    球蛋白(g/L)29.32 ± 4.1028.85 ± 3.9730.03 ± 4.20−4.146<0.001*
    血小板计数(×109/L)247.09 ± 78.73250.09 ± 83.34242.58 ± 71.101.3610.174
    血小板压积(%)0.25 ± 0.070.26 ± 0.070.25 ± 0.061.0270.305
    游离T3(pmol/L)4.64 ± 0.644.66 ± 0.664.61 ± 0.621.1660.244
    总蛋白(g/L)76.28 ± 4.8175.60 ± 4.7577.30 ± 4.73−5.120<0.001*
    血糖(mmol/L)5.29 ± 1.875.11 ± 1.725.56 ± 2.05−3.4850.001*
      *P < 0.05。
    下载: 导出CSV

    表  2  模型最佳参数表

    Table  2.   Optimal model parameters

    机器学习算法 超参数
    LR 'C':10 'solver':liblinear
    RF 'max_depth':20 'n_estimators':200
    DT 'max_depth':5 'min_samples_split':2
    XGBoost 'max_depth':6 'n_estimators':100
    CatBoost 'iterations':200 'learning_rate':0.1
    MLP 'activation':tanh 'hidden_layer_sizes':(50,)
    'alpha':0.001 'activation':constant
    下载: 导出CSV

    表  3  模型评价指标

    Table  3.   Model evaluation metrics

    机器学习算法SensitivitySpecificityF1值AccuracyRecall
    LR0.8383840.7428570.7942580.7892160.838384
    RF0.9090910.9428570.9230770.9264710.909091
    DT0.8585860.8857140.8673470.8725490.858586
    CatBoost0.898990.9333330.9128210.9166670.89899
    XGBoost0.898990.9333330.9128210.9166670.89899
    MLP0.7474750.9428570.8268160.8480390.747475
    下载: 导出CSV

    表  4  外部验证组人口统计学和临床特征比较[($ \bar x \pm s $)/n(%)]

    Table  4.   Demographic and clinical characteristics of the external validation group [($ \bar x \pm s $)/n(%)]

    变量总数(n=20)健康组(n=10)高血压组(n=10)t/χ2P
    女性15 (75.00)8 (80.00)7 (70.00)0.30.582
    服药史10 (50.00)2 (20.00)8 (80.00)7.20.001*
    年龄(岁)58.80 ± 9.8752.80 ± 6.2364.80 ± 9.17−3.4210.003*
    体重(kg)59.10 ± 9.0257.72 ± 8.8760.47 ± 9.07−0.6810.505
    身高(cm)157.30 ± 6.47159.60 ± 6.20155.00 ± 6.461.6240.122
    BMI (kg/m2)23.72 ± 3.2322.64 ± 3.2324.80 ± 2.92−1.5680.134
    收缩压 (mmHg)141.22 ± 30.64121.34 ± 10.82161.10 ± 30.63−3.8560.001*
    舒张压(mmHg)90.18 ± 18.2379.15 ± 7.15101.20 ± 18.66−3.4910.003*
    白细胞计数(×109/L)6.80 ± 1.716.98 ± 1.346.61 ± 2.060.4720.643
    总胆固醇(mmol/L)5.46 ± 0.845.41 ± 0.795.50 ± 0.94−0.2240.825
    低密度脂蛋白(mmol/L)3.13 ± 0.793.19 ± 0.613.06 ± 0.980.3550.727
    甘油三酯(mmol/L)1.70 ± 0.991.43 ± 0.541.96 ± 1.28−1.1890.250
    高密度脂蛋白(mmol/L)1.37 ± 0.351.33 ± 0.411.41 ± 0.31−0.490.630
    红细胞计数(×1012/L)4.94 ± 0.334.84 ± 0.255.03 ± 0.39−1.2910.213
    红细胞压积(%)46.86 ± 4.4145.00 ± 4.1448.72 ± 4.07−2.0250.058
    肌酐(μmol/L)75.00 ± 10.2274.90 ± 7.7275.10 ± 12.82−0.0420.967
    淋巴细胞计数(×109/L)32.22 ± 8.4429.20 ± 7.3735.23 ± 8.84−1.6560.115
    尿素(mmol/L)5.21 ± 1.684.80 ± 1.375.62 ± 1.93−1.0940.288
    尿酸(μmol/L)303.04 ± 98.78286.95 ± 45.41319.13 ± 132.84−0.7180.482
    球蛋白(g/L)28.83 ± 4.4828.65 ± 3.4829.00 ± 5.48−0.170.867
    血小板计数(×109/L)266.85 ± 69.34259.70 ± 90.08274.00 ± 42.17−0.4570.653
    血小板压积(%)0.29 ± 0.080.28 ± 0.100.29 ± 0.05−0.2820.781
    总蛋白(g/L)76.76 ± 4.5476.74 ± 3.5476.78 ± 5.61−0.0190.985
    血糖(mmol/L)5.53 ± 1.685.31 ± 0.745.74 ± 2.27−0.5730.574
      *P < 0.05。
    下载: 导出CSV

    表  5  外部验证数据预测结果

    Table  5.   Prediction results of external validation data

    类别 LR(%) RF(%) DT(%) CatBoost(%) XGBoost(%) MLP(%)
    高血压10010010010010080
    非高血压100100100100100100
    平均值10010010010010090
    下载: 导出CSV

    表  6  高血压影响因素的Logistic回归分析

    Table  6.   Logistic regression analysis of influencing factors for hypertension

    变量 $ B $ $ SE $ Wald $ P $ OR(95%CI)
    Drug 2.823594 0.201469 196.420267 <0.001* 16.8373(11.3444~24.9898)
    Weight 0.01376 0.008905 2.387592 0.122 1.0139(0.9963~1.0317)
    SBP 0.031011 0.006053 26.243928 <0.001* 1.0315(1.0193~1.0438)
    DBP −0.013126 0.010052 1.705157 0.192 0.9870(0.9677~1.0066)
    UA 0.005373 0.001229 19.110173 <0.001* 1.0054(1.0030~1.0078)
      *P < 0.05。
    下载: 导出CSV
  • [1] Forouzanfar M H, Alexander L, Anderson H R, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015, 386(10010): 2287-2323. doi: 10.1016/S0140-6736(15)00128-2
    [2] Brauer M, Roth G A, Aravkin A Y, et al. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440): 2162-2203. doi: 10.1016/S0140-6736(24)00933-4
    [3] 国家心血管病中心, 中国心血管健康与疾病报告编写组, 胡盛寿. 中国心血管健康与疾病报告2025概要[J]. 中国循环杂志, 2026, 41(6): 527-563. doi: 10.3969/j.issn.1000-3614.2026.06.002
    [4] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中国医疗保健国际交流促进会高血压病学分会, 等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志, 2024, 32(7): 603-700.
    [5] Mathur P, Srivastava S, Xu X, et al. Artificial intelligence, machine learning, and cardiovascular disease[J]. Clin Med Insights Cardiol, 2020, 14: 117954682092740.
    [6] Flores A M, Demsas F, Leeper N J, et al. Leveraging machine learning and artificial intelligence to improve peripheral artery disease detection, treatment, and outcomes[J]. Circ Res, 2021, 128(12): 1833-1850. doi: 10.1161/CIRCRESAHA.121.318224
    [7] Krittanawong C, Zhang H, Wang Z, et al. Artificial intelligence in precision cardiovascular medicine[J]. J Am Coll Cardiol, 2017, 69(21): 2657-2664. doi: 10.1016/j.jacc.2017.03.571
    [8] Ma J, Li Y, Yang X, et al. Signaling pathways in vascular function and hypertension: Molecular mechanisms and therapeutic interventions[J]. Signal Transduct Target Ther, 2023, 8(1): 168. doi: 10.1038/s41392-023-01430-7
    [9] Tsoi K, Yiu K, Lee H, et al. Applications of artificial intelligence for hypertension management[J]. J Clinical Hypertension, 2021, 23(3): 568-574. doi: 10.1111/jch.14180
    [10] 娄莹, 蔡军. 防线前移时不我待: 中国高血压积极防控的时代已来[J]. 协和医学杂志, 2024, 15(6): 1238-1241. doi: 10.12290/xhyxzz.2024-0774
    [11] Meher M, Pradhan S, Pradhan S R. Risk factors associated with hypertension in young adults: A systematic review[J]. Cureus, 2023, 15(4): e37467. doi: 10.7759/cureus.37467
    [12] You J, Guo Y, Kang J J, et al. Development of machine learning-based models to predict 10-year risk of cardiovascular disease: A prospective cohort study[J]. Stroke Vasc Neurol, 2023, 8(6): 475-485. doi: 10.1136/svn-2023-002332
    [13] 谭含璇, 林吉怡, 占平云, 等. 人工智能在高血压管理中的发展、机遇和挑战[J]. 中华高血压杂志, 2024, 32(12): 1101-1105. doi: 10.16439/j.issn.1673-7245.2024.12.001
    [14] Islam S M S, Talukder A, Awal M A, et al. Machine learning approaches for predicting hypertension and its associated factors using population-level data from three south Asian countries[J]. Front Cardiovasc Med, 2022, 9: 839379. doi: 10.3389/fcvm.2022.839379
    [15] 翁雯浩. Prediction and evaluation of hypertension risk based on multimodal feature fusion[J]. Modeling and Simulation, 2025, 14(02): 506-520.
    [16] Andishgar A, Bazmi S, Tabrizi R, et al. Machine learning-based models to predict the conversion of normal blood pressure to hypertension within 5-year follow-up[J]. PLoS One, 2024, 19(3): e0300201. doi: 10.1371/journal.pone.0300201
    [17] Wu Y, Xin B, Wan Q, et al. Risk factors and prediction models for cardiovascular complications of hypertension in older adults with machine learning: A cross-sectional study[J]. Heliyon, 2024, 10(6): e27941. doi: 10.1016/j.heliyon.2024.e27941
    [18] Montagna S, Pengo M F, Ferretti S, et al. Machine learning in hypertension detection: A study on world hypertension day data[J]. J Med Syst, 2022, 47(1): 1. doi: 10.21203/rs.3.rs-2250493/v1
    [19] 郭威, 田晶, 王雅靖, 等. 预测高血压合并射血分数保留的心力衰竭患者死亡风险的可解释机器学习模型[J]. 中华高血压杂志(中英文), 2025, 33(5): 434-443 .
    [20] Chowdhury M Z I, Leung A A, Walker R L, et al. A comparison of machine learning algorithms and traditional regression-based statistical modeling for predicting hypertension incidence in a Canadian population[J]. Sci Rep, 2023, 13: 13. doi: 10.1038/s41598-022-27264-x
    [21] Visco V, Izzo C, Mancusi C, et al. Artificial intelligence in hypertension management: An ace up your sleeve[J]. J Cardiovasc Dev Dis, 2023, 10(2): 74. doi: 10.3390/jcdd10020074
    [22] Ali Nematollahi M, Jahangiri S, Asadollahi A, et al. Body composition predicts hypertension using machine learning methods: A cohort study[J]. Sci Rep, 2023, 13: 6885. doi: 10.1038/s41598-023-34127-6
    [23] Islam M M, Alam M J, Maniruzzaman M, et al. Predicting the risk of hypertension using machine learning algorithms: A cross sectional study in Ethiopia[J]. PLoS One, 2023, 18(8): e0289613. doi: 10.1371/journal.pone.0289613
    [24] Zhong X, Yu J, Jiang F, et al. A risk prediction model based on machine learning for early cognitive impairment in hypertension: Development and validation study[J]. Front Public Health, 2023, 11: 1143019. doi: 10.3389/fpubh.2023.1143019
    [25] Anggraini D. Risk factors of hypertension in the elderly[J]. Nusantara Hasana Journal, 2024, 3(8): 12-20.
    [26] Champaneria M K, Patel R S, Oroszi T L. When blood pressure refuses to budge: Exploring the complexity of resistant hypertension[J]. Front Cardiovasc Med, 2023, 10: 1211199. doi: 10.3389/fcvm.2023.1211199
    [27] Debora C, Tolimba C, Palunggi S, et al. Risk factors for hypertension among adults living in a rural area, minahasa[J]. J Keperawatan Indonesia, 2023, 26(1): 36-45.
    [28] Wang Y, Ye C, Kong L, et al. Independent associations of education, intelligence, and cognition with hypertension and the mediating effects of cardiometabolic risk factors: A Mendelian randomization study[J]. Hypertension, 2023, 80(1): 192-203. doi: 10.1161/HYPERTENSIONAHA.122.20286
    [29] Perticone M, Maio R, Shehaj E, et al. Sex-related differences for uric acid in the prediction of cardiovascular events in essential hypertension. A population prospective study[J]. Cardiovasc Diabetol, 2023, 22(1): 298. doi: 10.1186/s12933-023-02006-z
    [30] Muszyński P, Dąbrowski E J, Pasławska M, et al. Hyperuricemia as a risk factor in hypertension among patients with very high cardiovascular risk[J]. Healthcare, 2023, 11(17): 2460. doi: 10.3390/healthcare11172460
    [31] Kim I J, Kim W, Go T H, et al. Validation of age- and sex-dependent association of uric acid and incident hypertension in rural areas[J]. Clin Hypertens, 2022, 28: 24. doi: 10.1186/s40885-022-00206-5
    [32] Borghi C, Agnoletti D, Cicero A F G, et al. Uric acid and hypertension: A review of evidence and future perspectives for the management of cardiovascular risk[J]. Hypertension, 2022, 79(9): 1927-1936. doi: 10.1161/HYPERTENSIONAHA.122.17956
  • [1] 景海卿, 杨春艳, 刘杰, 陈斌, 吴艳蕊, 苏婷, 付义.  基于网络药理学联合机器学习算法揭示天龙竭治疗特发性肺纤维化的作用机制, 昆明医科大学学报. 2026, 47(10): 24-44. doi: 10.12259/j.issn.2095-610X.S20261003
    [2] 李菡燚, 孙华钰, 李欣, 袁逸爽, 陈莹, 王兴培, 张以涛, 张亚芬, 李丽菊.  成人血脂异常风险关联模型的构建与初步验证, 昆明医科大学学报. 2026, 47(7): 62-70. doi: 10.12259/j.issn.2095-610X.S20260708
    [3] 刘娜娜, 赵艳华, 徐健, 王春英.  夜班负荷联合护理指标预测老年住院跌倒风险, 昆明医科大学学报. 2026, 48(): 1-13.
    [4] 廖元盛, 李恒, 廖芸, 胡云光, 殷安国, 孔美君, 刘龙丁, 张莹.  机器学习预测IAV和SARS-CoV-2感染引起心脏并发症中的共同靶点基因及H1N1感染模型验证, 昆明医科大学学报. 2025, 46(5): 75-88. doi: 10.12259/j.issn.2095-610X.S20250509
    [5] 廉坤, 李咏梅, 施诚龙, 陈怡兰, 张磊, 杨薇, 许秀峰.  综合生物信息学方法识别精神分裂症状中关键线粒体自噬基因, 昆明医科大学学报. 2025, 46(1): 23-35. doi: 10.12259/j.issn.2095-610X.S20250104
    [6] 曾慧娟, 田波, 袁红伶, 何杰, 李冠羲, 茹国佳, 许敏, 詹东.  机器学习算法构建慢性肾脏病伴高血压或糖尿病的预测模型, 昆明医科大学学报. 2024, 45(3): 99-105. doi: 10.12259/j.issn.2095-610X.S20240315
    [7] 李柳, 王亚茹, 张娣, 陈勤聪, 王明, 王硕.  高血压个体化用药基因检测在Ⅲ级高血压患者中的应用, 昆明医科大学学报. 2022, 43(4): 112-117. doi: 10.12259/j.issn.2095-610X.S20220430
    [8] 唐顺定, 万崇华, 宋莹, 邓丽, 王涵, 苏昌炜, 张晓磬.  高血压患者报告的临床结局测定量表的应用考评, 昆明医科大学学报. 2022, 43(3): 60-66. doi: 10.12259/j.issn.2095-610X.S20220312
    [9] 王秀清, 龙欣甜, 毛勇, 陈洁, 周佳, 楚天舒, 王松梅, 孙承欢, 赖纯米, 张倩.  怒族老年人高血压检出率及其影响因素, 昆明医科大学学报. 2021, 42(9): 40-45. doi: 10.12259/j.issn.2095-610X.S20210922
    [10] 母凤婷, 母昌宏, 何利平, 李晓梅, 张文佳, 喻箴, 杨庆欢, 柯红琴.  德宏傣族和景颇族高血压现状及影响因素, 昆明医科大学学报. 2021, 42(8): 54-59. doi: 10.12259/j.issn.2095-610X.S20210810
    [11] 龙欣甜, 陈洁, 毛勇, 王秀清, 卢双艳, 普惠婕, 周佳, 孙承欢, 王松梅, 叶爱芳.  安宁市老年人高血压检出率及其影响因素, 昆明医科大学学报. 2021, 42(12): 11-16. doi: 10.12259/j.issn.2095-610X.S20211210
    [12] 董玲, 彭云珠, 黄橙, 黄钊, 陈丽星.  云南大理白族高血压患病率及相关危险因素流行病学调查, 昆明医科大学学报. 2018, 39(07): 52-57.
    [13] 伏忠阳, 易婧.  氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床观察, 昆明医科大学学报. 2017, 38(10): 117-119.
    [14] 李文宏.  不同血液净化方式对维持血透患者高血压的影响, 昆明医科大学学报. 2015, 36(03): -1.
    [15] 庞兴美.  彩色多普勒超声对高血压患者颈动脉粥样硬化的诊断分析, 昆明医科大学学报. 2014, 35(04): -.
    [16] 章体玲.  阿托伐他汀对高血压合并房颤患者脉压及动脉弹性的临床疗效观察, 昆明医科大学学报. 2014, 35(09): -1.
    [17] 李鸿飞.  心理干预对32例地震后老年高血压合并焦虑障碍患者的临床治疗分析, 昆明医科大学学报. 2014, 35(05): -.
    [18] 张利刚.  依那普利叶酸治疗H型高血压的临床效果观察, 昆明医科大学学报. 2014, 35(06): -.
    [19] 杨峥.  氧化应激与血压和高血压发病关系的研究, 昆明医科大学学报. 2013, 34(10): -.
    [20] 陈学强.  靶控输注丙泊酚对高原高血压病人全麻诱导时血压变异性的影响, 昆明医科大学学报. 2011, 32(02): -.
  • 加载中
图(5) / 表(6)
计量
  • 文章访问数:  264
  • HTML全文浏览量:  136
  • PDF下载量:  3
  • 被引次数: 0
出版历程
  • 收稿日期:  2025-11-17
  • 网络出版日期:  2026-11-02

目录

    /

    返回文章
    返回